达格列净与心脏手术后急性肾损伤:一项随机临床试验
这项多中心、双盲、安慰剂对照RCT在荷兰2家学术中心和5家非学术医院纳入784例择期心脏手术成人,1:1随机接受达格列净10 mg口服每日1次(n=392)或安慰剂(n=392),从术前1天至术后第2天共4剂。主要终点为术后7天内KDIGO标准AKI。房颤和再次手术为最常见不良事件,两组发生率相近。提示围术期短期达格列净可减少择期心脏手术后AKI。
要点
- 主要终点AKI采用KDIGO标准:术后48小时内血肌酐升高≥0.3 mg/dL(26.5 µmol/L)、术后7天内肌酐升至1.5倍,或尿量<0.5 mL/kg/h持续6-12小时。
- 不良事件中房颤最常见(达格列净组45% vs 安慰剂组45%),再次手术分别为11% vs 10%,两组相近。
- 研究人群为择期心脏手术成人,中位年龄68岁、76%男性、97%白人、中位eGFR 80 mL/min/1.73 m2,结果外推需谨慎。
- 该方案为研究用围术期短期给药方案,非通用推荐;急诊/ICU中非择期心脏手术或已发生AKI者不适用。
适用人群与场景
- 纳入:荷兰2家学术医疗中心和5家非学术医院中接受择期心脏手术的成人, enrollment 2023年6月8日至2025年1月27日。
- 排除人群:原文未提及具体排除标准。
- 研究人群特征:中位年龄68(61-74)岁,76%男性,97%白人,中位BMI 27(25-30),中位eGFR 80(67-89)mL/min/1.73 m2。
- 场景:择期心脏手术围术期,非急诊/ICU非择期场景。
诊断标准与关键阈值
- AKI诊断采用KDIGO标准:术后48小时内血清肌酐升高≥0.3 mg/dL(26.5 µmol/L),或术后7天内肌酐升至基线1.5倍,或尿量<0.5 mL/kg/h持续6-12小时。
- 主要终点为术后前7天内上述AKI的发生。
处置流程与药物剂量
- 第一步:择期心脏手术成人术前1天开始口服达格列净10 mg,每日1次。
- 第二步:继续每日1次至术后第2天,总共4剂。
- 对照:安慰剂每日1次,同时间方案。
- 目标:降低术后7天内KDIGO标准AKI发生率。
红旗征与不能漏的情况
- 原文未提及需要立刻处理或不能漏诊的红旗征及对应处理。
研究设计与关键结果
- 研究类型:多中心、双盲、安慰剂对照随机临床试验,荷兰2家学术医疗中心和5家非学术医院,纳入784例择期心脏手术成人,1:1随机(达格列净n=392,安慰剂n=392),778例(99%)完成随访检测。
- 干预:达格列净10 mg口服每日1次,术前1天开始至术后第2天共4剂;对照:安慰剂同方案。
- 关键不良事件:房颤发生率两组均为45%(176/392 vs 176/392);再次手术分别为11%(43/392) vs 10%(39/392)。
证据类型、等级与局限
- 证据类型:随机临床试验(RCT),多中心、双盲、安慰剂对照。
- 证据等级或推荐强度:原文未提及。
- 局限:原文未明确列出局限;设计上为荷兰单国多中心研究,人群97%白人、76%男性,随访7天,样本784例。
对床旁实践的改变
- 可改变的做法:对择期心脏手术成人,可考虑术前1天起口服达格列净10 mg每日1次至术后第2天(共4剂)以降低术后7天AKI发生率。
- 适用人群:择期心脏手术成人,中位eGFR 80 mL/min/1.73 m2,研究方案条件下。
- 不适用人群:非择期心脏手术、急诊/ICU已发生AKI者原文未研究,不应外推。
- 常见陷阱:该4剂方案为研究用围术期短期方案,非通用推荐;不得将RR 0.54当作个体决策阈值;房颤和再次手术发生率两组相近,不能归因于达格列净。
指南或共识出处
- 原文未提及指南或共识名称;试验注册号ClinicalTrials.gov NCT05590143。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Two percent to 50% of patients undergoing elective cardiac surgery experience acute kidney injury (AKI) postoperatively. Medications to prevent AKI after elective cardiac surgery have not been identified.
OBJECTIVE: In patients undergoing elective cardiac surgery, to evaluate whether initiating dapagliflozin 1 day prior to surgery reduces the incidence of AKI at 7 days after cardiac surgery, compared with placebo.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled randomized clinical trial conducted at 2 academic medical centers and 5 nonacademic hospitals in the Netherlands. Eligible participants were adults undergoing elective cardiac surgery. Enrollment occurred between June 8, 2023, and January 27, 2025. Final follow-up occurred May 16, 2025.
INTERVENTION: Patients were randomized 1:1 to receive either dapagliflozin (10 mg orally; n = 392) or placebo once daily (n = 392), beginning on the day before surgery and continuing through the second postoperative day (total of 4 doses).
MAIN OUTCOME AND MEASURE: The primary outcome was the between-group difference in AKI (defined as an increase in serum creatinine level by at least 0.3 mg/dL [26.5 µmol/L] within 48 hours after surgery, a 1.5-fold creatinine increase within 7 days of surgery, or urine output less than 0.5 mL/kg/h for 6 to 12 hours according to Kidney Disease: Improving Global Outcomes criteria) during the first 7 postoperative days.
RESULTS: Of 784 participants enrolled, 778 (99%) completed follow-up testing (median age, 68 [61-74] years; 76% male; 97% White; median body mass index, 27 [IQR, 25-30]; and median estimated glomerular filtration rate, 80 [IQR, 67-89] mL/min/1.73 m2). Compared with placebo, dapagliflozin reduced the incidence of AKI (28% vs 52%; relative risk, 0.54 [95% CI, 0.45-0.65]; P < .001) over 7-day follow-up after surgery. Atrial fibrillation and reoperation were the most frequent adverse events. The incidence of atrial fibrillation was 45% (176/392) in the dapagliflozin group vs 45% (176/392) in the placebo group, and the incidence of reoperation was 11% (43/392) vs 10% (39/392), respectively.
CONCLUSIONS AND RELEVANCE: In patients undergoing elective cardiac surgery, 4 doses of dapagliflozin, beginning the day before surgery, reduced the incidence of AKI during the 7-day postoperative period.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05590143.
参考来源
- Oosterom-Eijmael MJP, Hulst AH, de Oliveira NPM, et al. Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial. JAMA. 2026. PMID: 42530910. doi:10.1001/jama.2026.9268
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。